The U.S. government has selected the second batch of drugs up for Medicare price negotiations under the Inflation Reduction ...

The Centers for Medicare and Medicaid Services (CMS) released its second round of drug negotiation targets, a list of 15 ...

Ozempic and Wegovy, Novo Nordisk’s GLP-1 drugs that treat diabetes and obesity, are on the list. Astellas Pharma’s prostate cancer drug, Xtandi, is also on the list — alongside AstraZeneca’s cancer ...

Bristol-Myers Squibb and AstraZeneca first joined forces to enable the companies to work together in order to research, develop and commercialise select investigational drugs for type 2 diabetes.

Novo Nordisk (NYSE: NVO) and AstraZeneca (NASDAQ: AZN) are among the largest companies in the pharmaceutical industry. Both ...

On Friday, the U.S. Department of Health and Human Services (HHS) unveiled the selection of 15 additional drugs covered under ...

Glucagon-like peptide-1 (GLP-1) analogs also known as incretin mimetics are class of drugs indicated for type-2 diabetes mellitus to lower the blood sugar level Mr. Shah Coherent Market Insights Pvt.

AstraZeneca's strategy is different from Novo Nordisk's. Whereas the latter derives most of its revenue from a few diabetes or obesity drugs, AstraZeneca has a large and diversified pipeline of ...

The talks around drugs including Novo Nordisk's Wegovy, GSK's Trelegy Ellipta, and Pfizer's Xtandi will set Medicare prices ...

The U.S. government targets Novo Nordisk's drugs, including Ozempic and Wegovy, for Medicare price negotiations in 2027.

In a report released on January 15, David Evans from Kepler Capital maintained a Hold rating on AstraZeneca (AZN – Research Report), with a ...

In November, Amneal Pharmaceuticals announced the FDA approved a generic version of AstraZeneca ... diabetes. Liraglutide is one of several GLP-1 receptor agonists currently on the FDA’s drug ...